Table 2 Characteristics of the 17 trials included in meta-analysis
Study | Eligible patients | Mobilization regimen | No. of patients | Age* | Gender (male%) |
|---|---|---|---|---|---|
Studies for MM | Â | Â | Â | Â | Â |
Bouko et al. [26] | Newly diagnosed MM, responders to 3–4 cycles of induction therapy | G-CSF SD | 23 | NA | NA |
| Â | Â | Pegfilgrastim 12Â mg | 22 | NA | NA |
| Â | Â | Pegfilgrastim 18Â mg | 22 | NA | NA |
Czerw et al. [30] | MM patients, age 18–65 years, CR or PR achieved after at least one line of therapy | G-CSF SD | 46 | 60 (37–65) | 57% |
|  |  | ID-AraC + G-CSF SD | 44 | 56 (33–65) | 61% |
DiPersio et al. [33] | Diagnosis of MM, age 18–78 years, in first or second CR or PR | G-CSF SD | 154 | 58.4 ± 8.6 | 68% |
|  |  | G-CSF SD + Plerixafor SD | 148 | 58.2 ± 8.4 | 70% |
Nahi et al. [50] | Diagnosis of MM, age ≥ 18 years, in CR or PR | G-CSF SD | 10 | 58 (42–69) | 60% |
|  |  | G-CSF SD + Plerixafor SD | 10 | 59 (43–70) | 40% |
Ri et al. [55] | Diagnosis of MM, age 20–75 years, in first or second CR or PR | G-CSF SD | 7 | 60 (49–67) | 57% |
|  |  | G-CSF SD + Plerixafor SD | 7 | 60 (38–71) | 57% |
Silvennoinen et al. [58] | Transplant-eligible MM patients aged ≤ 70 years | G-CSF SD | 35 | 63 (40–70) | 54% |
|  |  | CY + G-CSF RD | 34 | 62 (48–69) | 53% |
Skopec et al. [59] | Newly diagnosed MM treated with 3–6 cycles of Bor and Dex | G-CSF SD | 20 | 60 (35–69) | 55% |
|  |  | Pegfilgrastim 12 mg | 19 | 64 (51–71) | 47% |
Valtola et al. [61] | Transplant-eligible MM patients less than 70 years of age | G-CSF SD | 19 | 63 (52–70) | 42% |
|  |  | CY + G-CSF RD | 17 | 58 (49–70) | 59% |
Studies for NHL | Â | Â | Â | Â | Â |
DiPersio et al. [32] | Diagnosis of NHL, age 18–78 years, in first or second CR or PR | G-CSF SD | 148 | 59 (22–75) | 69% |
|  |  | G-CSF SD + Plerixafor SD | 150 | 56 (29–75) | 67% |
Kuruvilla et al. [43] | Diagnosis of NHL, age 18–78 years, in first or second CR or PR | G-CSF SD + Plerixafor SD | 31 | 47.8 ± 13.6 | 55% |
|  |  | G-CSF SD + Plerixafor FD | 30 | 46.1 ± 13.4 | 60% |
Liu et al. [44] | NHL patients, age 18–65 years, achieving CR or PR after first- or second-line therapy | G-CSF SD | 50 | 50 (18–64) | 50% |
|  |  | G-CSF SD + YF-H-2015005 | 51 | 45 (18–65) | 53% |
Matsue et al. [48] | Diagnosis of NHL, age 20–75 years, in first CR or PR | G-CSF SD | 16 | 63 (27–70) | 75% |
|  |  | G-CSF SD + Plerixafor SD | 16 | 56 (39–73) | 69% |
Zhu et al. [66] | Diagnosis of NHL, age 18–75 years, in first or second CR or PR | G-CSF SD | 50 | 43 (20–60) | 52% |
|  |  | G-CSF SD + Plerixafor SD | 50 | 39 (18–66) | 62% |